- Trial phase
- Unknown / Not publicly disclosed
- Time to market
- Not estimable; the drug candidate has no public presence.
- Why 0/10
- No hard, dated catalyst exists for ABCL386 because the drug could not be identified in any public source. Impact score is 0 as there is no evidence this is a real, disclosed program.
No actionable catalyst exists for ABCL386 because the drug candidate could not be identified in any public source. Investors should verify the correct drug code; AbCellera's next major catalyst is the advancement of ABCL635 into Phase 3 development, which the company guided for 2027 after positive Phase 2 data reported in August 2026.
Price Chart
Executive Summary
Extensive research across web searches, news databases, SEC filings, ClinicalTrials.gov, FDA records, and internal SecBot databases found zero mentions of a drug candidate called "ABCL386" from AbCellera Biologics or any other developer. AbCellera Biologics (NASDAQ: ABCL) is a real antibody discovery and development company, but its known proprietary pipeline consists of ABCL635 (Phase 2, menopausal hot flashes) and ABCL575 (Phase 1, atopic dermatitis). No evidence exists that ABCL386 is or was a publicly disclosed program.
How It Works
Not determinable from public sources. ABCL386 could not be identified as a disclosed drug candidate.
Trial Status
No clinical trials, regulatory filings, or press releases referencing ABCL386 were found in any public database.
The Two-Sided Case
Upcoming Catalysts
- None identified for ABCL386. For AbCellera broadly: Phase 3 initiation for ABCL635 guided for 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbCellera Biologics Inc. 8-K ABCL ·Originating report